<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2182-5173</journal-id>
<journal-title><![CDATA[Revista Portuguesa de Medicina Geral e Familiar]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Port Med Geral Fam]]></abbrev-journal-title>
<issn>2182-5173</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Medicina Geral e Familiar]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2182-51732017000100007</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Consumo de cafeína: o que aconselhar na preconceção e gravidez?]]></article-title>
<article-title xml:lang="en"><![CDATA[Caffeine consumption: what to recommend during preconception and pregnancy?]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Matias]]></surname>
<given-names><![CDATA[Filipa]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jeri]]></surname>
<given-names><![CDATA[Alice]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodrigues]]></surname>
<given-names><![CDATA[Sofia]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,ACeS Porto Oriental USF Novo Sentido ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
</aff>
<aff id="A02">
<institution><![CDATA[,ACeS Porto Oriental USF Barão de Nova Sintra ]]></institution>
<addr-line><![CDATA[Porto ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2017</year>
</pub-date>
<volume>33</volume>
<numero>1</numero>
<fpage>56</fpage>
<lpage>62</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2182-51732017000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2182-51732017000100007&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2182-51732017000100007&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivo: Rever a evidência sobre a associação entre consumo de cafeína em mulheres saudáveis - no período preconceção ou durante a gravidez - e o risco de abortamento espontâneo ou nado morto. Fontes de dados: Bases de dados MEDLINE, National Guideline Clearinghouse, Canadian Medical Association Practice Guidelines Infobase, Cochrane Library, Bandolier, DARE, Trip Datebase e Índex de Revistas Médicas Portuguesas. Métodos de revisão: Revisão baseada na evidência de artigos publicados nos últimos cinco anos (de 1 de agosto de 2010 a 31 de agosto de 2015), nas línguas inglesa, francesa, italiana, espanhola e portuguesa. Foram utilizados os termos MESH  caffeine ,  spontaneous abortion e  fetal death . Para avaliação do nível de evidência (NE) e força de recomendação foi utilizada a escala Strength of recommendation taxonomy, da American Family Physician. Resultados: Foram obtidos 84 artigos, dos quais quatro cumpriam os critérios de inclusão: três revisões sistemáticas com meta-análises (todas com NE 2) e um estudo coorte prospetivo (NE 1). Parece existir um aumento do risco de abortamento espontâneo ou nado morto com o consumo moderado a elevado de cafeína (superior a 100-150mg/dia) durante a gravidez. Não há evidência suficiente que demostre associação de risco no consumo durante a preconceção. Conclusões: O consumo moderado a elevado de cafeína durante a gravidez está associado ao aumento do risco de abortamento espontâneo e de nado morto (força de recomendação B), aconselhando-se um consumo nulo ou mínimo de cafeína (<100-150mg/dia) durante este período. Não há ainda evidência suficiente que demostre associação entre consumo durante a preconceção e a morte in utero. São necessários novos estudos que reforcem a evidência e definam as doses seguras de consumo de cafeína pela mulher nestes períodos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objective: To determine if there is a relationship between caffeine consumption during preconception and pregnancy and the occurrence of spontaneous abortion or stillbirth in healthy women. Data sources: MEDLINE database, National Guideline Clearinghouse, Canadian Medical Association Practice Guidelines Infobase, Cochrane Library, Bandolier, DARE, Trip Database, and Index of Portuguese medical journals. Methods: An evidence based review of relevant scientific papers published within the past five years (from 01/08/2010 to 31/08/2015), in English, French, Italian, Spanish and Portuguese was conducted. The MESH terms used were  caffeine ,  spontaneous abortion and  fetal death . To evaluate the levels of evidence (LE) and strength of recommendation, the authors used the Strength of recommendation taxonomy of the American Family Physician. Results: The search revealed 84 papers, four of which were included in this survey. We included three systematic reviews (all with LE 2) and one prospective cohort study (LE 1). These papers show an increased occurrence of spontaneous abortion or stillbirth with moderate-to-high consumption of caffeine (over 100-150mg/day) during pregnancy. There is insufficient evidence for an association between these adverse events and caffeine consumption during preconception. Conclusions: Moderate to high caffeine consumption during pregnancy increases the risk of spontaneous abortion and stillbirth (Strength of recommendation B). We recommend that caffeine consumption during this period should be reduced (<100-150mg/day) or completely avoided. There is insufficient evidence for recommendations regarding caffeine consumption during preconception. Better quality studies are needed to confirm the available evidence.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Cafeína]]></kwd>
<kwd lng="pt"><![CDATA[Abortamento espontâneo]]></kwd>
<kwd lng="pt"><![CDATA[Morte fetal]]></kwd>
<kwd lng="pt"><![CDATA[Nado morto]]></kwd>
<kwd lng="pt"><![CDATA[Gravidez]]></kwd>
<kwd lng="pt"><![CDATA[Preconceção]]></kwd>
<kwd lng="en"><![CDATA[Caffeine]]></kwd>
<kwd lng="en"><![CDATA[Spontaneous abortion]]></kwd>
<kwd lng="en"><![CDATA[Fetal death]]></kwd>
<kwd lng="en"><![CDATA[Stillbirth]]></kwd>
<kwd lng="en"><![CDATA[Pregnancy]]></kwd>
<kwd lng="en"><![CDATA[Preconception]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p align="right"><font size="2"><b>REVIS&#213;ES</b></font></p>     <p><font size="4"><b>Consumo de cafe&#237;na: o que aconselhar na   preconce&#231;&#227;o e gravidez?</b></font></p>     <p><font size="3"><b>Caffeine consumption: what to recommend during preconception and pregnancy?</b></font></p>     <p><b>Filipa Matias,<sup>1-2</sup> Alice Jeri,<sup>1-3</sup> Sofia Rodrigues<sup>1-2</sup></b></p>     <p>1. M&#233;dicas   Internas de Medicina Geral e Familiar</p>     <p>2. USF Novo   Sentido, ACeS Porto Oriental</p>     <p>3. USF Bar&#227;o   de Nova Sintra, ACeS Porto Oriental</p>     <p><a href="#c0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#c0">Direcci&oacute;n para correspondencia</a> | <a href="#c0">Correspondence</a><a name="topc0"></a></p> <hr/>     <p>&nbsp;</p>     <p><b>RESUMO</b></p>     ]]></body>
<body><![CDATA[<p><b>Objetivo:</b> Rever a evid&#234;ncia sobre a   associa&#231;&#227;o entre consumo de cafe&#237;na em mulheres saud&#225;veis - no per&#237;odo   preconce&#231;&#227;o ou durante a gravidez - e o risco de abortamento espont&#226;neo   ou nado morto.</p>     <p><b>Fontes de dados:</b> Bases de dados   MEDLINE, <i>National Guideline     Clearinghouse, Canadian Medical Association Practice Guidelines Infobase,     Cochrane Library, Bandolier,</i> DARE, <i>Trip       Datebase</i> e &#205;ndex de Revistas M&#233;dicas Portuguesas. </p>     <p><b>M&#233;todos de revis&#227;o:</b> Revis&#227;o baseada na   evid&#234;ncia de artigos publicados nos &#250;ltimos cinco anos (de 1 de agosto de 2010   a 31 de agosto de 2015), nas l&#237;nguas inglesa, francesa, italiana, espanhola e   portuguesa. Foram utilizados os termos MESH <i>&#8216;caffeine&#8217;,     &#8216;spontaneous abortion&#8217;</i> e <i>&#8216;fetal       death&#8217;.</i> Para avalia&#231;&#227;o do n&#237;vel de evid&#234;ncia (NE) e for&#231;a de recomenda&#231;&#227;o   foi utilizada a escala <i>Strength of     recommendation taxonomy,</i> da <i>American       Family Physician.</i></p>     <p><b>Resultados:</b> Foram obtidos 84 artigos,   dos quais quatro cumpriam os crit&#233;rios de inclus&#227;o: tr&#234;s revis&#245;es sistem&#225;ticas   com meta-an&#225;lises (todas com NE 2) e um estudo coorte prospetivo (NE 1). Parece   existir um aumento do risco de abortamento espont&#226;neo ou nado morto com o   consumo moderado a elevado de cafe&#237;na (superior a 100-150mg/dia) durante a   gravidez. N&#227;o h&#225; evid&#234;ncia suficiente que demostre associa&#231;&#227;o de risco no   consumo durante a preconce&#231;&#227;o.</p>     <p><b>Conclus&#245;es:</b> O consumo moderado a   elevado de cafe&#237;na durante a gravidez est&#225; associado ao aumento do risco de   abortamento espont&#226;neo e de nado morto (for&#231;a de recomenda&#231;&#227;o B),   aconselhando-se um consumo nulo ou m&#237;nimo de cafe&#237;na (&lt;100-150mg/dia)   durante este per&#237;odo. N&#227;o h&#225; ainda evid&#234;ncia suficiente que demostre associa&#231;&#227;o   entre consumo durante a preconce&#231;&#227;o e a morte <i>in utero.</i> S&#227;o necess&#225;rios novos estudos que reforcem a evid&#234;ncia e   definam as doses seguras de consumo de cafe&#237;na pela mulher nestes per&#237;odos.</p>     <p><b>Palavras-chave:</b> Cafe&#237;na; Abortamento   espont&#226;neo; Morte fetal; Nado morto; Gravidez; Preconce&#231;&#227;o</p> <hr/>     <p>&nbsp;</p>    <p><b>ABSTRACT</b></p>     <p><b>Objective:</b> To determine if there is a   relationship between caffeine consumption during preconception and pregnancy   and the occurrence of spontaneous abortion or stillbirth in healthy women.</p>     <p><b>Data sources:</b> MEDLINE database,   National Guideline Clearinghouse, Canadian Medical Association Practice   Guidelines Infobase, Cochrane Library, Bandolier, DARE, Trip Database, and   Index of Portuguese medical journals.</p>     ]]></body>
<body><![CDATA[<p><b>Methods:</b> An evidence based review of   relevant scientific papers published within the past five years (from   01/08/2010 to 31/08/2015), in English, French, Italian, Spanish and Portuguese   was conducted. The MESH terms used were &#8216;caffeine&#8217;, &#8216;spontaneous abortion&#8217; and   &#8216;fetal death&#8217;. To evaluate the levels of evidence (LE) and strength of   recommendation, the authors used the <i>Strength     of recommendation taxonomy</i> of the American Family Physician.</p>     <p><b>Results:</b> The search revealed 84 papers,   four of which were included in this survey. We included three systematic   reviews (all with LE 2) and one prospective cohort study (LE 1). These papers   show an increased occurrence of spontaneous abortion or stillbirth with   moderate-to-high consumption of caffeine (over 100-150mg/day) during pregnancy.   There is insufficient evidence for an association between these adverse events   and caffeine consumption during preconception.</p>     <p><b>Conclusions:</b> Moderate to high caffeine   consumption during pregnancy increases the risk of spontaneous abortion and   stillbirth (Strength of recommendation B). We recommend that caffeine   consumption during this period should be reduced (&lt;100-150mg/day) or   completely avoided. There is insufficient evidence for recommendations   regarding caffeine consumption during preconception. Better quality studies are   needed to confirm the available evidence.</p>     <p><b>Keywords:</b> Caffeine; Spontaneous abortion;   Fetal death; Stillbirth; Pregnancy; Preconception</p> <hr/>     <p>&nbsp;</p>    <p><b>Introdu&#231;&#227;o</b></p>     <p>A cafe&#237;na &#233;   uma subst&#226;ncia psicoativa, estimulante do sistema nervoso central. Est&#225;   presente em m&#250;ltiplos alimentos e bebidas como o caf&#233;, ch&#225;, chocolate,   refrigerantes, bebidas energ&#233;ticas, entre outros. O caf&#233;, uma das bebidas mais   consumidas a n&#237;vel mundial, &#233; a bebida mais frequentemente associada &#224; cafe&#237;na.<sup>1</sup> Em Portugal, o seu consumo ronda os 4,7kg/pessoa/ano, segundo os dados da <i>European Coffee Federation,</i><sup>2</sup> prevendo-se at&#233; 2021 um aumento deste valor, sobretudo no sexo feminino.<sup>3</sup></p>     <p>O consumo da   cafe&#237;na pode ter impacto na progress&#227;o da gravidez, uma vez que a subst&#226;ncia   atravessa a barreira placent&#225;ria e pode ser detetada no flu&#237;do amni&#243;tico. O   feto apresenta reduzida capacidade de metaboliza&#231;&#227;o da cafe&#237;na, a qual   prejudica o desenvolvimento celular do embri&#227;o ou feto.<sup>1</sup> Tal facto &#233;   tamb&#233;m potenciado pela diminui&#231;&#227;o da elimina&#231;&#227;o hep&#225;tica da cafe&#237;na que ocorre   durante a gravidez.</p>     <p>O mecanismo   atrav&#233;s do qual a cafe&#237;na compromete o crescimento fetal ainda permanece   incerto. Tem sido postulada a hip&#243;tese de que aumente a liberta&#231;&#227;o de   catecolaminas, levando &#224; vasoconstri&#231;&#227;o na circula&#231;&#227;o uteroplacent&#225;ria e   consequente hipoxia fetal, condicionando o seu crescimento e desenvolvimento.<sup>4</sup> Com efeito, foi documentada uma diminui&#231;&#227;o de 25% no fluxo placent&#225;rio   interviloso ap&#243;s a ingest&#227;o materna de apenas 200mg de cafe&#237;na.<sup>5</sup> Outra hip&#243;tese &#233; a de que a cafe&#237;na aumente a concentra&#231;&#227;o intracelular de   adenosina monofosfato c&#237;clico atrav&#233;s da inibi&#231;&#227;o da fosfodiesterase,   influenciando a divi-s&#227;o celular e afetando, desta forma, o crescimento fetal.<sup>6-7</sup></p>     <p>Poss&#237;veis   efeitos adversos gestacionais do consumo da cafe&#237;na incluem o abortamento   espont&#226;neo (antes das 22 semanas) e o nado morto (durante e ap&#243;s as 22 semanas).<sup>8-9</sup> Estas ocorr&#234;ncias s&#227;o frequentes na popula&#231;&#227;o em geral, tendo a busca de   fatores etiol&#243;gicos ambientais motivado extensas pesquisas nem sempre   conclusivas.<sup>10</sup> Outros poss&#237;veis efeitos adversos do consumo da   cafe&#237;na durante a gravidez incluem a diminui&#231;&#227;o no crescimento intrauterino, a   redu&#231;&#227;o do peso ao nascer e o risco de teratog&#233;nese.</p>     ]]></body>
<body><![CDATA[<p>Em   contraponto, sabe-se que os sintomas associados &#224; gravidez (como avers&#227;o a   paladares e odores, n&#225;useas e v&#243;mitos) s&#227;o mais comuns em gesta&#231;&#245;es saud&#225;veis   que resultar&#227;o em nados-vivos, sendo menos frequentes naquelas que terminar&#227;o   em abortamento espont&#226;neo.<sup>11</sup> Esta rela&#231;&#227;o &#233; atribu&#237;da a um <i>pregnancy signal</i> (concentra&#231;&#227;o de   hormonas grav&#237;dicas) mais forte, um sinal associado a uma gesta&#231;&#227;o vi&#225;vel. Foi   demonstrado que o consumo de cafe&#237;na tende a diminuir com o agravamento dos   sintomas associados &#224; gravidez durante as primeiras semanas, pelo que o menor   consumo poderia ser consequ&#234;ncia da viabilidade da gesta&#231;&#227;o (elevado <i>pregnancy signal</i>), ao inv&#233;s de um   elevado consumo ser causador de abortamento (efeito de causalidade inversa).   Estes sintomas podem, portanto, constituir-se como confundidores importantes   nos estudos.</p>     <p>Outro fator   de dif&#237;cil ajuste &#233; o tabagismo, frequentemente associado ao consumo de caf&#233; e   com riscos pr&#243;prios para a gesta&#231;&#227;o, alterando adicionalmente a metaboliza&#231;&#227;o   da cafe&#237;na.<sup>12</sup></p>     <p>As   recomenda&#231;&#245;es atuais relativamente &#224; quantidade permitida de consumo de cafe&#237;na   durante a gravidez s&#227;o d&#237;spares, aconselhando-se geralmente ingest&#227;o di&#225;ria   inferior a 200-300mg/dia.<sup>13-14</sup> As quantidades m&#233;dias aproximadas de cafe&#237;na doseada em bebidas e alimentos mais comuns est&#227;o descritas no <a href="#q1">Quadro I</a>.</p>     <p>&nbsp;</p>    <p align="center"><a name="q1"></a><img src="/img/revistas/rpmgf/v33n1/33n1a07q1.jpg"/></p>    
<p>&nbsp;</p>     <p>O presente   trabalho tem como objetivo rever a evid&#234;ncia sobre a associa&#231;&#227;o entre consumo   de cafe&#237;na em mulheres saud&#225;veis - no per&#237;odo preconce&#231;&#227;o ou durante a   gravidez - e o risco de abortamento espont&#226;neo ou nado morto.</p>     <p><b>M&#233;todo</b></p>     <p>Realizou-se   uma pesquisa bibliogr&#225;fica de normas de orienta&#231;&#227;o cl&#237;nica (NOC), revis&#245;es   sistem&#225;ticas, meta-an&#225;lises, estudos originais nas bases de dados MEDLINE, <i>National Guideline Clearinghouse, Canadian     Medical Association Practice Guidelines Infobase, Cochrane Library,</i> Bandolier, DARE, <i>Trip Datebase</i> e   &#205;ndex de Revistas M&#233;dicas Portuguesas de artigos publicados nos &#250;ltimos cinco   anos, de 1 de agosto de 2010 a 31 de agosto de 2015, nas l&#237;nguas inglesa,   francesa, italiana, espanhola e portuguesa. Foram utilizados os termos MESH <i>&#8216;caffeine&#8217;, &#8216;spontaneous abortion&#8217;</i> e <i>&#8216;fetal death&#8217;.</i> Foram tamb&#233;m utilizados   os termos em portugu&#234;s &#8220;cafe&#237;na&#8221;, &#8220;abortamento espont&#226;neo&#8221; e &#8220;morte fetal&#8221; na   pesquisa no &#205;ndex de Revistas M&#233;dicas Portuguesas. A pesquisa bibliogr&#225;fica foi   feita no dia 1 de setembro de 2015.</p>     <p>Definiram-se   como crit&#233;rios de inclus&#227;o:</p>     ]]></body>
<body><![CDATA[<p>&#8226; Popula&#231;&#227;o:   mulheres saud&#225;veis em per&#237;odo de preconce&#231;&#227;o e/ou gr&#225;vidas;</p>     <p>&#8226;   Interven&#231;&#227;o: consumo de produtos com cafe&#237;na em doses vari&#225;veis;</p>     <p>&#8226;   Compara&#231;&#227;o: aus&#234;ncia, ou consumo m&#237;nimo (&lt;100-150mg/dia), de produtos com   cafe&#237;na;</p>     <p>&#8226; <i>Outcome: </i>ocorr&#234;ncia de casos de   abortamento espont&#226;neo ou nado morto.</p>     <p>Foram   exclu&#237;das mulheres com antecedentes patol&#243;gicos ou fatores de risco conhecidos,   em tratamento de fertilidade, com hist&#243;ria de abortamentos de repeti&#231;&#227;o ou com   consumo concomitante de outras subst&#226;ncias potencialmente t&#243;xicas, com exce&#231;&#227;o   do tabaco.</p>     <p>Para   avalia&#231;&#227;o do n&#237;vel de evid&#234;ncia (NE) e for&#231;a de recomenda&#231;&#227;o (FR) foi utilizada   a escala <i>Strength of recommendation     taxonomy</i> (SORT),<sup>15</sup> da <i>American       Family Physician</i> (<a href="#q2">Quadro II</a>). Para avalia&#231;&#227;o da qualidade metodol&#243;gica dos   artigos foram utilizados os crit&#233;rios de <i>Downs</i> e <i>Black</i> e aplicado o <i>Appraisal of Guidelines Research &amp;     Evaluation Instrument</i> (AGREE) na avalia&#231;&#227;o das NOCs.<sup>16-18</sup></p>     <p>&nbsp;</p>    <p align="center"><a name="q2"></a><img src="/img/revistas/rpmgf/v33n1/33n1a07q2.jpg"/></p>    
<p>&nbsp;</p>     <p><b>Resultados</b></p>     ]]></body>
<body><![CDATA[<p>A pesquisa   inicial identificou 84 artigos, dos quais se exclu&#237;ram cinco por se encontrarem   duplicados e 75 por n&#227;o se enquadrarem no objetivo da revis&#227;o, por n&#227;o   cumprirem crit&#233;rios de inclus&#227;o ou por n&#227;o revelarem qualidade metodol&#243;gica   (essencialmente por pouca qualidade de informa&#231;&#227;o e validade interna). Ap&#243;s a   aplica&#231;&#227;o do AGREE, os autores n&#227;o recomendam a inclus&#227;o da NOC encontrada,   particularmente devido &#224; baixa pontua&#231;&#227;o auferida nos dom&#237;nios de rigor de   desenvolvimento, clareza da apresenta&#231;&#227;o e aplicabilidade. Foram inclu&#237;dos   quatro artigos: tr&#234;s revis&#245;es sistem&#225;ticas com meta-an&#225;lise e um estudo de   coorte prospetivo. O fluxograma da sele&#231;&#227;o dos estudos encontra-se explanado na   <a href="#f1">Figura 1</a>.</p>     <p>&nbsp;</p>    <p align="center"><a name="f1"></a><img src="/img/revistas/rpmgf/v33n1/33n1a07f1.jpg"/></p>    
<p>&nbsp;</p>     <p>A revis&#227;o   sistem&#225;tica com meta an&#225;lise elaborada por Li e colaboradores, em 2015,   englobou 26 estudos: 13 estudos caso-controlo e 13 estudos de coorte. Destes,   apenas 20 abordavam o consumo de cafe&#237;na. Foi utilizada uma an&#225;lise   quantitativa para detetar a eventual associa&#231;&#227;o entre o consumo de cafe&#237;na   durante a gesta&#231;&#227;o e a perda da gravidez (atrav&#233;s de question&#225;rios, entrevistas   e registos cl&#237;nicos), explorando uma rela&#231;&#227;o dose-resposta. Nesta an&#225;lise foi   considerada exposi&#231;&#227;o ligeira &#224; cafe&#237;na como consumo inferior a 150mg/dia;   exposi&#231;&#227;o moderada entre 150 e 300mg/dia; e exposi&#231;&#227;o elevada quando consumo   igual ou superior a 301mg/dia. Os limites temporais para o abortamento   espont&#226;neo abrangeram o per&#237;odo antes das 20 semanas, sendo a n&#227;o-evolu&#231;&#227;o   posterior da gravidez considerada como nado morto.</p>     <p>Globalmente,   o consumo de cafe&#237;na associou-se ao aumento do risco de abortamento espont&#226;neo   ou nado morto - <i>Odds Ratio</i> (OR)   1,47 (<i>p</i>&lt;0,01; intervalo de   confian&#231;a (IC) 95% 1,31-1,66; heterogeneidade (I<sup>2</sup>)=70,9%). Foi   encontrado um efeito dose-resposta a partir do consumo de 149,5mg/dia, n&#227;o se   estabelecendo associa&#231;&#227;o para a exposi&#231;&#227;o ligeira. Tamb&#233;m se verificou um   aumento no risco de 19% para cada aumento de 150mg/dia no consumo de cafe&#237;na   - OR 1,19 (IC 95% 1,16-1,23). Apesar de se encontrar marcada   heterogeneidade entre os estudos na primeira an&#225;lise, esta deixou de ser   significativa ap&#243;s a exclus&#227;o de dois estudos espec&#237;ficos (I<sup>2</sup>=48%),   mantendo-se a associa&#231;&#227;o. De referir que os autores apontaram como limita&#231;&#227;o   desta revis&#227;o um poss&#237;vel vi&#233;s de publica&#231;&#227;o (pesquisa realizada apenas na   MEDLINE) (NE 2) (<a href="#q3">Quadro III</a>).</p> <    <p>&nbsp;</p>    <p align="center"><a name="q3"></a><img src="/img/revistas/rpmgf/v33n1/33n1a07q3.jpg"/></p>    
<p>&nbsp;</p>     <p>Na revis&#227;o   sistem&#225;tica com meta-an&#225;lise de Greenwood e colaboradores, de 2014, foram   inclu&#237;dos 53 estudos observacionais. Com relev&#226;ncia para os <i>outcomes</i> deste trabalho foram   considerados, relativamente ao abortamento espont&#226;neo, 26 estudos (14 estudos   de coorte e 12 casos-controlo); e, relativamente ao nado morto, cinco estudos   (tr&#234;s estudos de coorte e dois casos-controlo). Nesta an&#225;lise foi estimado o   consumo de cafe&#237;na atrav&#233;s da convers&#227;o dos produtos em cafe&#237;na, atribuindo   100mg de cafe&#237;na por unidade de caf&#233; e 60mg de cafe&#237;na por unidade de outras   fontes (ch&#225; ou coca-cola&#174;).</p>     ]]></body>
<body><![CDATA[<p>No que   concerne ao abortamento espont&#226;neo (definido neste estudo como morte <i>in utero</i> antes das 24 semanas de   gesta&#231;&#227;o), a meta-an&#225;lise dos dados encontrou um risco relativo (RR) de 1,14 a   partir do consumo de 100mg/dia de cafe&#237;na, com uma rela&#231;&#227;o dose-resposta linear   (<i>p</i>&lt;0,001; IC 95% 1,10-1,19, I<sup>2</sup>=89%).   Dada a elevada heterogeneidade verificada foi exclu&#237;do o estudo com maior   impacto na variabilidade, o que resultou na redu&#231;&#227;o da heterogeneidade (RR   1,11; IC 95% 1,07-1,14; I<sup>2</sup>&lt;44%), mantendo-se a rela&#231;&#227;o   inicialmente encontrada. Assim, demonstrou-se um aumento discreto, mas   consistente, da incid&#234;ncia de abortamento espont&#226;neo com o aumento do consumo   di&#225;rio de cafe&#237;na.</p>     <p>Relativamente   ao nado morto (definido como morte <i>in     utero</i> ap&#243;s as 24 semanas de gesta&#231;&#227;o), a meta-an&#225;lise dos dados encontrou   um RR de 1,19 a partir do consumo de 100mg/dia de cafe&#237;na, com rela&#231;&#227;o   dose-resposta linear (<i>p</i>=0,007; IC 95%   1,05-1,35, I<sup>2</sup>=82%). Tamb&#233;m aqui se verificou elevada   heterogeneidade, tendo sido reduzida ap&#243;s estratifica&#231;&#227;o de um estudo que   apenas considerou o consumo de caf&#233; como fonte de cafe&#237;na (I<sup>2</sup>&lt;50%),   mantendo-se a rela&#231;&#227;o inicialmente encontrada. Foi poss&#237;vel demonstrar um   aumento discreto, mas consistente, da incid&#234;ncia de nado morto com o aumento do   consumo di&#225;rio de cafe&#237;na.</p>     <p>Como   conclus&#227;o, esta revis&#227;o sistem&#225;tica aconselha que a mulher gr&#225;vida n&#227;o   ultrapasse os 200mg de consumo di&#225;rio de cafe&#237;na (NE 2) (<a href="#q3">Quadro III</a>).</p>     <p>Na revis&#227;o   sistem&#225;tica com meta-an&#225;lise de Lassi e colaboradores, de 2014, foram inclu&#237;dos   39 estudos, dos quais apenas nove se referiam ao consumo de cafe&#237;na no per&#237;odo   preconcecional. Foi feita a avalia&#231;&#227;o do risco com a estratifica&#231;&#227;o do consumo   de cafe&#237;na inferior a 150mg/dia; maior a 300mg/dia, 420mg/dia e 900mg/dia,   estimativa feita atrav&#233;s da quantidade de bebida aferida atrav&#233;s de question&#225;rios.</p>     <p>Demonstrou-se   que o consumo de cafe&#237;na superior a 300mg/dia durante a preconce&#231;&#227;o aumentou o   risco de nado morto (RR 1,31; <i>p</i>=0,005;   IC 95% 1,08-1,58), elevando-se o risco com o aumento do consumo (superior a   420mg/dia de cafe&#237;na: RR 6,11; <i>p</i>&lt;0,0001;   IC 95% 5,12-7,29). N&#227;o houve evid&#234;ncia estatisticamente significativa do   aumento do risco com consumos superiores a 900mg/dia (RR 1,72; <i>p</i>=0,05; IC 95% 1,00-2,96). Verificou-se   elevada heterogeneidade entre os estudos, n&#227;o tendo sido poss&#237;vel diminui-la   devido ao reduzido n&#250;mero de estudos inclu&#237;dos. Em rela&#231;&#227;o ao abortamento   espont&#226;neo, verificou-se um aumento n&#227;o significativo do risco com o consumo   di&#225;rio de cafe&#237;na na preconce&#231;&#227;o.</p>     <p>Assim, esta   revis&#227;o sistem&#225;tica aferiu que o consumo elevado de cafe&#237;na (superior a   300mg/dia) durante a preconce&#231;&#227;o aumenta o risco de nado morto, sendo   necess&#225;ria investiga&#231;&#227;o adicional para averiguar a rela&#231;&#227;o causal entre o   consumo de cafe&#237;na e risco de abortamento espont&#226;neo. N&#227;o obstante, &#233;   aconselhado um consumo m&#237;nimo ou nulo de cafe&#237;na durante a preconce&#231;&#227;o (NE 2)   (<a href="#q3">Quadro III</a>).</p>     <p>O estudo   original de seguimento de uma coorte prospetiva, elaborado por Hahn e   colaboradores em mar&#231;o de 2015, acompanhou 5.132 mulheres dinamarquesas, com   idades entre os 18 e os 40 anos, que planeavam engravidar sem tratamento de   fertilidade. Este estudo avaliou a exposi&#231;&#227;o &#224; cafe&#237;na (caf&#233; ou outras bebidas)   atrav&#233;s de question&#225;rios de auto-preenchimento. Estes question&#225;rios foram   preenchidos em v&#225;rios momentos: na preconce&#231;&#227;o, durante a gravidez e, se   aplic&#225;vel, aquando da cl&#237;nica de aborto espont&#226;neo. No question&#225;rio era   explicitada a quantidade de por&#231;&#245;es, em ml ou por recipiente, consumida por   semana de: caf&#233; (250ml, caneca), caf&#233; descafe&#237;nado (250ml, caneca), ervas para   infus&#227;o/verde (250ml, caneca), ch&#225; preto (250ml, caneca), cola normal (500ml,   garrafa) e cola <i>light</i> (500ml,   garrafa). Foram consideradas as seguintes doses de cafe&#237;na em mg, cada dose:   caf&#233; 141mg, caf&#233; descafe&#237;nado 5mg, ch&#225; preto 56mg, cola normal 51mg e cola <i>light</i> 60mg. Avaliaram-se potenciais   vari&#225;veis confundidoras utilizando regress&#227;o de Cox - idade materna,   paridade, tabagismo, hist&#243;ria de abortos espont&#226;neos, consumo de &#225;lcool,   atividade f&#237;sica, peso e altura e habilita&#231;&#245;es liter&#225;rias.</p>     <p>Registou-se   um <i>follow up</i> adequado, com um   seguimento de 87% da popula&#231;&#227;o. Os resultados mostraram que, na popula&#231;&#227;o, uma   amostra de 732 mulheres teve um aborto espont&#226;neo. No per&#237;odo preconce&#231;&#227;o, o   consumo de cafe&#237;na n&#227;o foi associado a um risco substancial de aborto   espont&#226;neo. O <i>hazard ratios</i> (HR) de   consumo de cafe&#237;na &#8805;300mg/dia foi de 1,09 (IC 95% 0,89-1,33) em   compara&#231;&#227;o com 100mg/dia. Consumos no in&#237;cio da gravidez de 100-199, 200-299 e   maior ou igual a 300mg de cafe&#237;na/dia mostraram HR de 1,62 (IC 95% 1,19-2,22),   1,48 (IC 95% 1,03-2,13) e 1,23 (IC 95% 0,61-2,46), respetivamente,   comparativamente a consumos &lt;100mg/dia.</p>     <p>Nesta coorte   prospetiva conclui-se que o consumo de cafe&#237;na, principalmente durante a   gravidez, foi associado a um risco ligeiramente maior de aborto espont&#226;neo,   pelo que o consumo deve ser desaconselhado, ainda que a evid&#234;ncia da rela&#231;&#227;o   dose-resposta demonstrada tenha sido reduzida.</p>     <p>Como   limita&#231;&#245;es, os autores deste estudo original apontaram a aus&#234;ncia da colheita   di&#225;ria de hormona gonadotr&#243;fica cori&#243;nica humana, com preju&#237;zo da taxa de   dete&#231;&#227;o de abortos espont&#226;neos; o vi&#233;s de fiabilidade da informa&#231;&#227;o fornecida   pela mulher (relativa aos seus consumos) e a poss&#237;vel varia&#231;&#227;o individual no   metabolismo da cafe&#237;na, devido a polimorfismos gen&#233;ticos, que afete a   quantidade de cafe&#237;na em circula&#231;&#227;o, a qual n&#227;o foi estudada (NE 1) (<a href="#q4">Quadro IV</a>).</p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>    <p align="center"><a name="q4"></a><img src="/img/revistas/rpmgf/v33n1/33n1a07q4.jpg"/></p>    
<p>&nbsp;</p>     <p><b>Conclus&#227;o</b></p>     <p>O consumo   di&#225;rio de cafe&#237;na moderado a elevado durante a gesta&#231;&#227;o parece estar associado   a um aumento do risco de abortamento espont&#226;neo ou nado morto, propondo-se   ingest&#245;es inferiores a 100-150mg/dia nesta fase (for&#231;a de recomenda&#231;&#227;o B).   Relativamente ao consumo durante a preconce&#231;&#227;o n&#227;o h&#225; ainda evid&#234;ncia   suficiente que demonstre associa&#231;&#227;o entre o consumo de cafe&#237;na e morte <i>in utero.</i></p>     <p>Os autores   ressalvam a inexist&#234;ncia de normas de orienta&#231;&#227;o cl&#237;nica robustas acerca deste   tema e a exist&#234;ncia apenas de estudos de natureza observacional, dadas as   limita&#231;&#245;es &#233;ticas que restringem a experimenta&#231;&#227;o no per&#237;odo grav&#237;dico. De   salientar que este tipo de estudos poder&#225; estar associado a um poss&#237;vel vi&#233;s de   mem&#243;ria. A utiliza&#231;&#227;o de diferentes defini&#231;&#245;es temporais de abortamento   espont&#226;neo e nado morto, n&#227;o correspondentes &#224;s aceites na legisla&#231;&#227;o   portuguesa, constituiu uma limita&#231;&#227;o importante. Outra limita&#231;&#227;o prende-se com   a real quantifica&#231;&#227;o do consumo di&#225;rio de cafe&#237;na - quer pela inclus&#227;o de   diferentes fontes de cafe&#237;na na alimenta&#231;&#227;o, divergente entre estudos; quer   devido &#224; utiliza&#231;&#227;o de diferentes tabelas de estimativa de quantidade de   cafe&#237;na por quantidade/por&#231;&#227;o de alimento, potenciada pela elevada   variabilidade intercultural da quantidade de cafe&#237;na, conforme o tipo de caf&#233; e   a forma de prepara&#231;&#227;o; quer devido &#224; variabilidade nos intervalos de consumo   definidos nos diferentes trabalhos. O ajuste para potenciais vari&#225;veis   confundidoras, como o consumo tab&#225;gico e a idade materna, nem sempre foi   realizado. A redu&#231;&#227;o do consumo de cafe&#237;na na presen&#231;a de sintomas associados a   um <i>pregnancy signal</i> elevado n&#227;o foi   despistada. Tamb&#233;m n&#227;o foram estudadas varia&#231;&#245;es individuais do metabolismo da   cafe&#237;na devidas a polimorfismos gen&#233;ticos.</p>     <p>A   import&#226;ncia desta tem&#225;tica na pr&#225;tica cl&#237;nica fundamenta a realiza&#231;&#227;o de   estudos mais abrangentes, com ajuste metodol&#243;gico adequado para as vari&#225;veis   confundidoras identificadas e assegurando a quantifica&#231;&#227;o precisa dos consumos   de cafe&#237;na na popula&#231;&#227;o em estudo.</p>     <p>N&#227;o   obstante, a presente revis&#227;o baseada na evid&#234;ncia recomenda que as mulheres   gr&#225;vidas, ou que ponderam engravidar, devem restringir ao m&#237;nimo o seu consumo   di&#225;rio de cafe&#237;na. Dado o caf&#233; ser o produto com cafe&#237;na mais comummente   consumido na nossa cultura, e tendo em conta a elevada concentra&#231;&#227;o de cafe&#237;na   no caf&#233;, aconselham-se as mulheres gr&#225;vidas ou que ponderem engravidar a   restringir o consumo de caf&#233; a uma ch&#225;vena por dia.</p>     <p>Deve-se   ainda alertar as mulheres para a presen&#231;a de cafe&#237;na noutros produtos,   sugerindo uma leitura atenta dos seus r&#243;tulos.</p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><b>REFER&#202;NCIAS BIBLIOGR&#193;FICAS</b></p>     <!-- ref --><p>1. Patel S,   Rizzolo D. Q: is caffeine safe during pregnancy? J Am Acad Physician Assist.   2012;25(5):69.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367497&pid=S2182-5173201700010000700001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>2. European   Coffee Federation. European coffee report 2013/14: European chapter and key   national data (Internet). Brussels: ECF; 2014. Available from: <a href="http://www.stc-coffee.com/wp-content/uploads/2014/08/European_Coffee_Report_2013-14_European_chapter.pdf" target="_blank">http://www.stc-coffee.com/wp-content/uploads/2014/08/European_Coffee_Report_2013-14_European_chapter.pdf</a>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367499&pid=S2182-5173201700010000700002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>3. Oliveira   T, Dias RR. Perspectivas e tend&#234;ncias sociais no consumo de caf&#233; em Portugal   para 2021. In: Dias RR, Afonso JC, editors. Marketing agroalimentar:   fundamentos e estudos de caso. Lisboa: Vida Econ&#243;mica; 2015. p. 243-54.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367500&pid=S2182-5173201700010000700003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ISBN   9789897680892</p>     <!-- ref --><p>4. Kirkinen   P, Jouppila P, Koivula A, Vuori J, Puukka M. The effect of caffeine on   placental and fetal blood flow in human pregnancy. Am J Obstet Gynecol.   1983;147(8):939-42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367502&pid=S2182-5173201700010000700004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>5. CARE   Study Group. Maternal caffeine intake during pregnancy and risk of fetal growth   restriction: a large prospective observational study. BMJ. 2008;337:a2332.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367504&pid=S2182-5173201700010000700005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>6. Grosso   LM, Rosenberg KD, Belanger K, Saftlas AF, Leaderer B, Bracken MB. Maternal   caffeine intake and intrauterine growth retardation. Epidemiology.   2001;12(4):447-55.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367506&pid=S2182-5173201700010000700006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>7. Soyka LF.   Effects of methylxanthines on the fetus. Clin Perinatol. 1979;6(1):37-51.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367508&pid=S2182-5173201700010000700007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>8.   Administra&#231;&#227;o Central do Sistema de Sa&#250;de. As semanas de gesta&#231;&#227;o na   codifica&#231;&#227;o da obstetr&#237;cia (Internet). Lisboa: ACSS; 2011 (cited 2015 Sep 1). Available from: <a href="http://portalcodgdh.min-saude.pt/index.php/As_semanas_de_gesta%C3%A7%C3%A3o_na_codifica%C3%A7%C3%A3o_da_obstetr%C3%ADcia" target="_blank">http://portalcodgdh.min-saude.pt/index.php/As_semanas_de_gesta%C3%A7%C3%A3o_na_codifica%C3%A7%C3%A3o_da_obstetr%C3%ADcia</a> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367510&pid=S2182-5173201700010000700008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>9. Ouyang F,   Zhang J, Betr&#225;n AP, Yang Z, Souza JP, Merialdi M. Recurrence of adverse   perinatal outcomes in developing countries. Bull World Health Organ.   2013;91(5):357-67.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367511&pid=S2182-5173201700010000700009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>10. Li J,   Zhao H, Song JM, Zhang J, Tang YL, Xin CM. A meta-analysis of risk of pregnancy   loss and caffeine and coffee consumption during pregnancy. Int J Gynaecol   Obstet. 2015;130(2):116-22.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367513&pid=S2182-5173201700010000700010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>11. Peck JD,   Leviton A, Cowan LD. A review of the epidemiologic evidence concerning the   reproductive health effects of caffeine consumption: a 2000-2009 update. Food   Chem Toxicol. 2010;48(10):2549-76.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367515&pid=S2182-5173201700010000700011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>12.   Greenwood DC, Thatcher NJ, Ye J, Garrard L, Keogh G, King LG, et al. Caffeine   intake during pregnancy and adverse birth outcomes: a systematic review and   dose-response meta-analysis. Eur J Epidemiol. 2014;29(10):725-34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367517&pid=S2182-5173201700010000700012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>13. Gra&#231;a   LM. Medicina materno-fetal. 4&#170; ed. Lisboa: LIDEL; 2010.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367519&pid=S2182-5173201700010000700013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --> ISBN 9789727576548</p>     <!-- ref --><p>14. National   Institute for Health and Care Excellence. Antenatal care for uncomplicated   pregnancies (CG62) (Internet). London: NICE; 2008 (updated 2017 Jan). Available from: <a href="https://www.nice.org.uk/guidance/cg62" target="_blank">https://www.nice.org.uk/guidance/cg62</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367521&pid=S2182-5173201700010000700014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>15. Ebell   MH, Siwek J, Weiss BD, Woolf SH, Susman J, Ewingman B, et al. Strength of   recommendation taxonomy (SORT): a patient-centered approach to grading evidence   in the medical literature. Am Fam Physician. 2004;69(3):548-56.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367522&pid=S2182-5173201700010000700015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>16. Downs   SH, Black N. The feasibility of creating a checklist for the assessment of the   methodological quality both of randomised and non-randomised studies of health   care interventions. J Epidemiol Community Health. 1998;52(6):377-84.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367524&pid=S2182-5173201700010000700016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     ]]></body>
<body><![CDATA[<!-- ref --><p>17. AGREE   Collaborations. Development and validation of an international appraisal   instrument for assessing the quality of clinical practice guidelines: the AGREE   project. Qual Saf Health Care. 2003;12(1):18-23.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367526&pid=S2182-5173201700010000700017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>18. Brouwers   M, Kho ME, Browman GP, Cluzeau F, Feder G, Fervers B, et al. AGREE II:   advancing guideline development, reporting and evaluation in healthcare   (Internet). The AGREE Research Trust; 2009 (cited 2009 Sep 1) Available from: <a href="http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf" target="_blank">http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-item-Instrument_2009_UPDATE_2013.pdf</a>  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367528&pid=S2182-5173201700010000700018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --><!-- ref --><p>19. Lassi   ZS, Imam AM, Dean SV, Bhutta ZA. Preconception care: caffeine, smoking,   alcohol, drugs and other environmental chemical/radiation exposure. Reprod   Health. 2014;11 Suppl 3:S6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367529&pid=S2182-5173201700010000700019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>20. Hahn KA,   Wise LA, Rothman KJ, Mikkelsen EM, Brogly SB, S&#248;rensen HT, et al. Caffeine and   caffeinated beverage consumption and risk of spontaneous abortion. Hum Reprod.   2015;30(5):1246-55.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367531&pid=S2182-5173201700010000700020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>21. Mitchell   DC, Knight CA, Hockenberry J, Teplansky R, Hartman TJ. Beverage caffeine intake   in the U.S. Food Chem Toxicol. 2014;63:136-42.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367533&pid=S2182-5173201700010000700021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>22. Harland   BF. Caffeine and nutrition. Nutrition. 2000;16(7-8):522-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367535&pid=S2182-5173201700010000700022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <!-- ref --><p>23. McCusker   RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal   Toxicol. 2003;27(7):520-2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1367537&pid=S2182-5173201700010000700023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></p>     <p>&nbsp;</p>     <p><a href="#topc0">Endere&ccedil;o para correspond&ecirc;ncia</a> | <a href="#topc0">Direcci&oacute;n para correspondencia</a> | <a href="#topc0">Correspondence</a><a name="c0"></a></p>      <p>Filipa   Alexandra Lopes Matias</p>     <p>R. Calouste   Gulbenkian, n&#186; 237-1H1, 4465-040 Porto</p>     <p>E-mail: <a href="mailto:filipamatias.mgf@gmail.com">filipamatias.mgf@gmail.com</a>   </p>     <p>&nbsp;</p>     <p><b>Conflitos de interesse</b></p>     ]]></body>
<body><![CDATA[<p>As autoras   declaram n&#227;o ter conflitos de interesse.</p>     <p>&nbsp;</p>     <p><b>Recebido em 13-02-2016</b></p>     <p><b>Aceite para publica&#231;&#227;o em 16-11-2016</b></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rizzolo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Q: is caffeine safe during pregnancy?]]></article-title>
<source><![CDATA[J Am Acad Physician Assist]]></source>
<year>2012</year>
<volume>25</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>69</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>European Coffee Federation</collab>
<source><![CDATA[European coffee report 2013/14: European chapter and key national data]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[ECF]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Perspectivas e tendências sociais no consumo de café em Portugal para 2021]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Dias]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Afonso]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Marketing agroalimentar: fundamentos e estudos de caso]]></source>
<year>2015</year>
<page-range>243-54</page-range><publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[Vida Económica]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kirkinen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jouppila]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Koivula]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vuori]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puukka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of caffeine on placental and fetal blood flow in human pregnancy]]></article-title>
<source><![CDATA[Am J Obstet Gynecol]]></source>
<year>1983</year>
<volume>147</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>939-42</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<collab>CARE Study Group</collab>
<article-title xml:lang="en"><![CDATA[Maternal caffeine intake during pregnancy and risk of fetal growth restriction: a large prospective observational study]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2008</year>
<volume>337</volume>
<page-range>a2332</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grosso]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenberg]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Belanger]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saftlas]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Leaderer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bracken]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Maternal caffeine intake and intrauterine growth retardation]]></article-title>
<source><![CDATA[Epidemiology]]></source>
<year>2001</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>447-55</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soyka]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of methylxanthines on the fetus]]></article-title>
<source><![CDATA[Clin Perinatol]]></source>
<year>1979</year>
<volume>6</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>37-51</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>Administração Central do Sistema de Saúde</collab>
<source><![CDATA[As semanas de gestação na codificação da obstetrícia]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[ACSS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ouyang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Betrán]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Merialdi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recurrence of adverse perinatal outcomes in developing countries]]></article-title>
<source><![CDATA[Bull World Health Organ]]></source>
<year>2013</year>
<volume>91</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>357-67</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[YL]]></given-names>
</name>
<name>
<surname><![CDATA[Xin]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A meta-analysis of risk of pregnancy loss and caffeine and coffee consumption during pregnancy]]></article-title>
<source><![CDATA[Int J Gynaecol Obstet]]></source>
<year>2015</year>
<volume>130</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>116-22</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peck]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Leviton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cowan]]></surname>
<given-names><![CDATA[LD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A review of the epidemiologic evidence concerning the reproductive health effects of caffeine consumption: a 2000-2009 update]]></article-title>
<source><![CDATA[Food Chem Toxicol]]></source>
<year>2010</year>
<volume>48</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2549-76</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenwood]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Thatcher]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ye]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garrard]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Keogh]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[LG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Caffeine intake during pregnancy and adverse birth outcomes: a systematic review and dose-response meta-analysis]]></article-title>
<source><![CDATA[Eur J Epidemiol]]></source>
<year>2014</year>
<volume>29</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>725-34</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Graça]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicina materno-fetal]]></source>
<year>2010</year>
<edition>4</edition>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[LIDEL]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="book">
<collab>National Institute for Health and Care Excellence</collab>
<source><![CDATA[Antenatal care for uncomplicated pregnancies (CG62)]]></source>
<year>2008</year>
<publisher-loc><![CDATA[London ]]></publisher-loc>
<publisher-name><![CDATA[NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ebell]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Siwek]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[BD]]></given-names>
</name>
<name>
<surname><![CDATA[Woolf]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Susman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ewingman]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2004</year>
<volume>69</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>548-56</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Downs]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Black]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions]]></article-title>
<source><![CDATA[J Epidemiol Community Health]]></source>
<year>1998</year>
<volume>52</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>377-84</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[AGREE Collaborations]]></surname>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project]]></article-title>
<source><![CDATA[Qual Saf Health Care]]></source>
<year>2003</year>
<volume>12</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>18-23</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kho]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Browman]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
<name>
<surname><![CDATA[Cluzeau]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Feder]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fervers]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[AGREE II: advancing guideline development, reporting and evaluation in healthcare]]></source>
<year>2009</year>
<month>20</month>
<day>09</day>
<publisher-name><![CDATA[The AGREE Research Trust]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lassi]]></surname>
<given-names><![CDATA[ZS]]></given-names>
</name>
<name>
<surname><![CDATA[Imam]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Dean]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Bhutta]]></surname>
<given-names><![CDATA[ZA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Preconception care: caffeine, smoking, alcohol, drugs and other environmental chemical/radiation exposure]]></article-title>
<source><![CDATA[Reprod Health]]></source>
<year>2014</year>
<volume>11</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Wise]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Rothman]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mikkelsen]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Brogly]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Sørensen]]></surname>
<given-names><![CDATA[HT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Caffeine and caffeinated beverage consumption and risk of spontaneous abortion]]></article-title>
<source><![CDATA[Hum Reprod]]></source>
<year>2015</year>
<volume>30</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1246-55</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Knight]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Hockenberry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Teplansky]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hartman]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Beverage caffeine intake in the US]]></article-title>
<source><![CDATA[Food Chem Toxicol]]></source>
<year>2014</year>
<volume>63</volume>
<page-range>136-42</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Harland]]></surname>
<given-names><![CDATA[BF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Caffeine and nutrition]]></article-title>
<source><![CDATA[Nutrition]]></source>
<year>2000</year>
<volume>16</volume>
<numero>7-8</numero>
<issue>7-8</issue>
<page-range>522-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCusker]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Goldberger]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Cone]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Caffeine content of specialty coffees]]></article-title>
<source><![CDATA[J Anal Toxicol]]></source>
<year>2003</year>
<volume>27</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>520-2</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
